What Are Oligodendrocytes? Functions, Markers & Disease Links

Oligodendrocytes and Schwann cells are both glial cells involved in myelination, but they exhibit important differences in terms of location, myelination patterns, and developmental origins. Oligodendrocytes are found exclusively in the central nervous system, which comprises the brain and spinal cord. In contrast, Schwann cells are located in the peripheral nervous system, which includes the nerves outside of the CNS.

One significant distinction between oligodendrocytes and Schwann cells lies in their myelination patterns. Oligodendrocytes extend their processes to wrap around different segments of multiple axons, forming multiple layers of myelin sheath. This allows one oligodendrocyte to myelinate several axons simultaneously. On the other hand, Schwann cells envelop a single axon by spiraling around it, forming a single layer of myelin.

Additionally, oligodendrocytes and Schwann cells have different developmental origins. Oligodendrocytes originate from precursor cells within the CNS during embryonic development, while Schwann cells are derived from neural crest cells in the PNS. Despite these distinctions, both oligodendrocytes and Schwann cells play vital roles in supporting and insulating neurons. Their myelination processes contribute to the efficient and rapid transmission of electrical signals, ensuring the proper functioning of the nervous system.

Oligodendrocyte lineage markers and histology techniques play a crucial role in identifying and studying oligodendrocytes. Several marker proteins are used to pinpoint oligodendrocyte lineage cells, including:

• Oligodendrocyte transcription factor (OLIG) family proteins: These transcription factors, such as OLIG1 and OLIG2, are vital for oligodendrocyte development and function.
• Myelin basic protein (MBP): MBP is an essential protein for the formation and maintenance of the myelin sheath, a characteristic feature of oligodendrocytes.
• Oligodendrocyte-specific proteolipid protein (PLP): PLP is found in the myelin sheath and helps maintain its structural integrity.

Histology techniques are used to visualize oligodendrocytes and their characteristics. Hematoxylin and eosin (H&E) staining is commonly employed to observe the cellular morphology of oligodendrocytes. Immunohistochemistry enables the detection of specific oligodendrocyte lineage markers, including Olig-17 (a marker for oligodendrocyte progenitor cells), and CNPase (a marker for myelin-forming oligodendrocytes). Additionally, fluorescence microscopy can be utilized to visualize oligodendrocytes labeled with fluorescent probes, providing enhanced visualization capabilities.

Dysfunctional oligodendrocytes are associated with various diseases, including demyelinating diseases, neurodegenerative disorders, oligodendrogliomas, and leukodystrophies. Demyelinating diseases are characterized by the breakdown of the myelin sheath, leading to impaired nerve function and development. One example is multiple sclerosis (MS), an autoimmune disorder that attacks the myelin sheath, causing demyelination and axonal damage. Cerebral palsy, resulting from brain damage during development, can also affect oligodendrocytes and lead to motor function and coordination problems. Pelizaeus-Merzbacher disease, a hereditary disorder, results in the loss of myelin-forming oligodendrocytes. Traumatic brain injury (TBI) is another condition that can damage oligodendrocytes and cause demyelination, contributing to disability.

Neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, involve the dysfunction of oligodendrocytes and subsequent loss of neuronal function. These diseases are characterized by problems with memory, cognition, behavior, coordination, and movement. Oligodendrogliomas are tumors derived from oligodendrocytes. Although they are usually slow-growing and rarely metastasize, they can be challenging to treat due to their aggressive nature. Leukodystrophies encompass a group of hereditary disorders affecting the myelin sheath. These conditions can lead to movement difficulties, cognitive impairment, and other neurological dysfunctions. Examples of leukodystrophies include adrenoleukodystrophy (ALD) and metachromatic leukodystrophy (MLD).

Treatment strategies for oligodendrocyte disorders aim to manage symptoms and enhance the quality of life, although a cure is currently unavailable for most of these conditions. While the treatment options for oligodendrocyte disorders are still evolving, several strategies are being explored. Here are some of the treatment approaches currently considered:

• Immunomodulatory Therapies: In demyelinating disorders such as multiple sclerosis (MS), the immune system mistakenly attacks the myelin sheath. Medications known as disease-modifying therapies (DMTs) are used to modulate the immune response and reduce inflammation in order to slow disease progression and manage symptoms. Examples of DMTs include interferon-beta, glatiramer acetate, and monoclonal antibodies like natalizumab or ocrelizumab.
• Remyelination Therapies: Stimulating the regeneration of myelin is a key focus of research. Various approaches are being investigated, including the use of stem cells, which have the potential to differentiate into oligodendrocytes and promote remyelination. Other strategies involve the use of small molecules or biologics that enhance oligodendrocyte precursor cell differentiation and myelination.
• Neuroprotective Approaches: Oligodendrocyte disorders often involve neuronal damage in addition to demyelination. Protecting and preserving nerve cells from further injury is an important therapeutic goal. Neuroprotective strategies may involve the use of antioxidants, anti-inflammatory agents, or drugs that promote cell survival and repair.
• Symptomatic Treatment: Many oligodendrocyte disorders manifest with neurological symptoms that can be managed with symptomatic treatment. For example, medications may be prescribed to alleviate pain, muscle spasms, fatigue, or bladder dysfunction commonly seen in MS.
• Physical and Occupational Therapy: Rehabilitation approaches can play a significant role in optimizing function and quality of life for individuals with oligodendrocyte disorders. Physical and occupational therapies may focus on improving mobility, coordination, strength, and activities of daily living.

These treatment strategies may vary depending on the specific oligodendrocyte disorder and individual patient characteristics. The field of oligodendrocyte research is rapidly evolving, and new therapeutic strategies are continuously being explored in preclinical and clinical studies.

Marina Alberto, PhD, holds a robust academic background in Biotechnology, earning her Bachelor’s Degree and PhD in Science and Technology from Quilmes National University. Her research spans cancer immunotherapy, glycan profiling, and vaccine development, including innovative projects on pediatric leukemia diagnosis and cancer-associated carbohydrate-mimetic vaccines. She currently serves as a Technical Support and Sales Specialist at Assay Genie.